• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Longitudinal stability of cognitive impairments in post-COVID-19 syndrome assessed with the tablet-based Oxford Cognitive Screen-Plus

tetano

Editor, Senior Moderator
Sci Rep


. 2026 Apr 16;16(1):12589.
doi: 10.1038/s41598-026-48476-5.
Longitudinal stability of cognitive impairments in post-COVID-19 syndrome assessed with the tablet-based Oxford Cognitive Screen-Plus

Valeska Kozik[SUP] 1 [/SUP], Philipp A Reuken[SUP] 2 [/SUP], Katzer Katrin[SUP] 2 [/SUP], Zoe Stallmach[SUP] 2 [/SUP], Isabelle Utech[SUP] 3 [/SUP], Nele Demeyere[SUP] 4 [/SUP], Matthias Schwab[SUP] 3 [/SUP], Andreas Stallmach[SUP] 2 [/SUP], Kathrin Finke[SUP] 3 5 [/SUP]


Affiliations
Abstract

In a previous cross-sectional study using the tablet-based Oxford Cognitive Screen-Plus (OCS-Plus), deficits in delayed memory, attention, and executive functioning were identified in working-age patients with post-COVID-19 syndrome (PCS) following infection in 2020 or early 2021. Initial assessment occurred approximately five months after infection. To examine short-term longitudinal trajectories, patients were reassessed several months later. Eighty-one patients with PCS (mean age 46.6 years, 64% female) completed OCS-Plus assessments at baseline and after a median follow-up of 4.4 months. Cognitive change was analysed using Wilcoxon signed-rank tests and equivalence testing (± 1 SD of reference scores) to assess clinical relevance. Associations between cognitive change and changes in depression and fatigue were examined using bootstrap-corrected multiple regression. No significant change in cognitive performance was observed between baseline and follow-up across any cognitive domain (all p > 0.3). Equivalence testing indicated that observed differences fell within predefined bounds of clinical insignificance (all p < 0.01). Changes in depressive symptoms and fatigue were not associated with changes in cognitive performance. Across the observed follow-up period, domain-level cognitive performance remained stable, with no evidence of short-term spontaneous improvement. These findings suggest short-term longitudinal stability of cognitive impairments in PCS within the limits of screening-based assessment and the follow-up interval studied, supporting the value of continued cognitive monitoring in affected individuals.

Keywords: Cognitive Dysfunction; Digital Health; Longitudinal Studies; Neuropsychological Assessment; Post-COVID-19 Syndrome.

 
Back
Top